Vasculitis & polymyalgia rheumatica
Avacopan with combined cyclophosphamide and rituximab for induction therapy in severe anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: retrospective observational study of 30 patients in two German referral centres
Authors' conclusion
In this observational study, avacopan as GC-sparing agent appeared safe and efficacious in combination with RTX and CYC for remission induction in severe ANCA-associated vasculitis.
Study context
- Population
- Patients with severe AAV with renal and at least two further organ-threatening involvement, two German referral centres
- Participants
- 30 patients
- Outcome
- Remission
- Follow-up
- Week 24
Methodological detailstwo German referral centres
- Two German referral centres
Main finding
As reported in the abstract
- All patients achieved remission by week 24
Observational data: associations, not effects.
Further findings
Events
| Outcome | GC-free | GC-treated | OR (CI) | P value | |
|---|---|---|---|---|---|
| Dialysis dependency, GC-freevs GC-treated · week 24 | 1 | 4 | 0.12 (0.01–1.25) | P = 0.048 | |
| 0.050.21520Odds ratio (log scale) |
Safety
Avacopan discontinuation
- Discontinued due to urosepsis
- 1
- Discontinued due to refractory disease
- 1
Original publication
Avacopan with combined cyclophosphamide and rituximab for induction therapy in severe ANCA-associated vasculitis: retrospective observational study of 30 patients in two German referral centres. Clin Exp Rheumatol. Published 5 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →